精准微生物干预减少衰老相关性状试验 (PreMIS)
HIV感染者饮酒的老年保护精准医学策略
People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.
研究概览
详细说明
This is a randomized, double-blind, controlled, crossover mechanistic clinical trial in people with HIV who have recent alcohol use. Participants are randomized to receive either Limosilactobacillus reuteri probiotic or blueberry extract first for 4 weeks, followed by a 6-week washout period, then crossover to the alternate intervention for 4 weeks. Each participant receives both interventions.
Both interventions are generally recognized as safe (GRAS) dietary supplements and are not intended to diagnose, treat, cure, or prevent disease. This study is not conducted under an Investigational New Drug (IND) application and does not involve FDA-regulated investigational products.
Biospecimen collection and clinical assessments are performed at baseline and Week 4 of each intervention period. The primary analysis compares within-participant changes in immune senescence markers between interventions using a crossover design framework and accounts for period and sequence effects.
Participants will be recruited from HIV clinical care programs, affiliated clinics, and community outreach efforts in the New Orleans area.
A 6-week washout period is included to minimize potential carryover effects.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:David A Welsh, MD
- 电话号码:5045684634 United States
- 邮箱:dwelsh@lsuhsc.edu
学习地点
-
-
Louisiana
-
New Orleans、Louisiana、美国、70112
- 招聘中
- LSU Health
-
接触:
- David A Welsh, MD
- 电话号码:5045684634 United States
- 邮箱:dwelsh@lsuhsc.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥40 years
- People with HIV
- Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG)
Exclusion Criteria:
- Probiotic use in past 3 months
- Recent antibiotics or immunosuppressives
- Allergy to study products
- Pregnancy or breastfeeding
- Inability to comply
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Sequence A: Probiotic then Blueberry Extract
Participants receive probiotic for 4 weeks, washout 6 weeks, then blueberry extract for 4 weeks. |
Administered as 8 capsules daily (4 twice daily) for 4 weeks. Each daily dose contains 1×10^10 CFU total in a 1:1 ratio of two strains. This is a GRAS dietary supplement and not an FDA-regulated investigational product. Administered as 8 capsules daily (4 twice daily) for 4 weeks, providing 500 mg anthocyanins per day. This is a GRAS dietary supplement and not an FDA-regulated investigational product. |
|
实验性的:Sequence B: Blueberry Extract then Probiotic
Participants receive blueberry extract for 4 weeks, washout 6 weeks, then probiotic for 4 weeks. |
Administered as 8 capsules daily (4 twice daily) for 4 weeks. Each daily dose contains 1×10^10 CFU total in a 1:1 ratio of two strains. This is a GRAS dietary supplement and not an FDA-regulated investigational product. Administered as 8 capsules daily (4 twice daily) for 4 weeks, providing 500 mg anthocyanins per day. This is a GRAS dietary supplement and not an FDA-regulated investigational product. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in circulating senescent T cell numbers
大体时间:Time 0 to Week 4 of treatment period
|
Change in circulating CD3+CD8+CD28-CD38+ T cell count (cells/µL) during treatment period. Measured by multiparameter flow cytometry. The primary endpoint is the within-participant difference in change from baseline. |
Time 0 to Week 4 of treatment period
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in additional senescent T cell phenotypes
大体时间:Baseline and Week 4
|
Flow cytometry-defined subsets |
Baseline and Week 4
|
|
Change in epigenetic age estimation
大体时间:Baseline and Week 4
|
Change in DNA methylation-based age estimates using epigenetic clock analyses. |
Baseline and Week 4
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in additional senescent T cell phenotypes
大体时间:time 0 to 4 weeks
|
Exploratory analyses of additional T cell phenotypes including assess additional senescence markers including lysosomal-β-galactosidase (GLB1), proinflammatory SASP (IL-1β, IL-2, IL17A, IL-18, TNFa, IFNg, HMBG1), proliferation (Ki67), CD27, CD57, and DNA damage (p-H2A.X) in T cells at multiple stages of maturation including naïve, effector, memory, and TEMRA. |
time 0 to 4 weeks
|
|
Microbiome and metabolite profiles
大体时间:Baseline and Week 4
|
Stool microbiome (phylogenetic analysis and bacterial genes quantification) and metabolite analyses. |
Baseline and Week 4
|
合作者和调查者
调查人员
- 首席研究员:David A Welsh, MD、LSU Health New Orleans
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 8883
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified individual participant data will be shared upon reasonable request following publication, subject to data use agreements.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.